ClinicalTrials.gg
RecruitingNCT05955170TUC-TOCUpdated Mar 27, 2025

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

A Phase 2 interventional study of Tucatinib in Combination of Oral VP16 and trastuzumab in HER2-positive Breast Cancer, sponsored by Institut Curie. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Institut Curie · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Breast Neoplasms by Institut Curie — 7 open to participants now, 7 under way, 2 of them phase 3. Breast Neoplasms · Institut Curie.

Planned enrollment
22nd of 29
66 · median 155
Started
2023
with 2 others
Phase 2
6 of 35
2 open now
Registered
30th of 35
by date

Among the 35 studies in Breast Neoplasms by Institut Curie, this one is the 22nd largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 35 studies in Breast Neoplasms by Institut Curie are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Breast Neoplasms by Institut Curie, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.

Read the detailed description

This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.

The study has two sequential parts:

  • Part 1 is a safety run-in part evaluating the safety of the combination to confirm the recommended dose;
  • Part 2 will evaluate the efficacy of the combination at the recommended dose. Both parts will include patients with HER2 positive metastatic breast cancer.

In part 1, a D-dose is evaluated; only in case of unacceptable toxicity at the D-dose, a D-1 dose will be investigated.

In part 2, patients will be treated with oral VP16 at the dose recommended in part 1.

Dose reductions will be allowed on subsequent cycles in case of toxicity.

All enrolled patients will receive the combination of tucatinib, oral VP16, trastuzumab until disease progression, unacceptable toxicity, and withdrawal of patient consent, investigator decision, and loss to follow-up, death, patient non-compliance, or discontinuation of the study by the sponsor.

Tumor assessments should be performed according to RECIST v1.1 criteria at baseline and every 6 weeks (± 7 days) for the first 24 weeks, then every 9 weeks (± 7 days) until documented disease progression, withdrawal of consent, or death.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. First disease progression under tucatinib-capecitabine-trastuzumab. OR Medical to initiate or continue capecitabine in association with tucatinib-trastuzumab (investigator's decision based on patient medical history, DPD deficiency and/or capecitabine grade 2 toxicity or higher).
  2. Age > 18 years,
  3. confirmed + breast carcinoma (ASCO/CAP guidelines) with archived tumor tissue available,
  4. Have a of at least 3 months,
  5. (ECOG) performance status of 0 or 1,
  6. Participants must be able to swallow capsules,
  7. Participants must be able and willing to be available for the duration of the study and are willing to follow study procedures,
  8. , assessed by version 1,
  9. Patients with are eligible:

    • Unless urgent treatment is required
    • If time since WBRT is ≥ 21 days prior to first dose of treatment, time since SRS is ≥ 7 days prior to first dose of treatment, or time since surgical resection is ≥ 28 days
  10. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions
  11. (LVEF) ≥ 50% (within 4 weeks before inclusion)
  12. Adequate organ function (obtained within 14 days prior to treatment start) as evidenced by:

    o (ANC) ≥ 1.5 X 10\^9/L

    o (Hgb) ≥ 9 g/dL

    o count ≥ 100 X 10\^9/L

    • ≤ 1.5 X (ULN), except for patients with a documented history of Gilbert's disease (≤ 2 X ULN)
    • (ALT), and aspartate aminotransferase (AST) ≤ 2.5 X ULN (for patients with liver ≤ 5 X ULN);
    • Alkaline phosphatase (AP) ≤ 3 X ULN (for patients with liver metastases, ≤ 5 X ULN);
    • Serum creatinine ≤ 1.5 mg/dL (133 μmol/L) or calculated ≥ 50 mL/min (using Cockcroft-Gault formula).
  13. If the patient is female:

Women of (WCBP): negative serum pregnancy test. The patient must be willing to use effective methods of . Patients must be , surgically infertile, or willing to use a physical barrier method of contraception in addition to an intrauterine device or hormonal contraception until at least 6 months after completion of study treatment,

If the patient is male:

Male patients must agree to use an acceptable method of contraception (e.g., condom) during the study and for 3 months after completion of treatment, 14. Patients must be covered by a health insurance plan. 15. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have previously been treated with:

    a. lapatinib within 12 months of starting study treatment (except in cases where lapatinib was given for ≤ 21 days and was discontinued for reasons other than disease progression or severe toxicity) b. neratinib, afatinib, or other / EGFR or HER2 TKI at any time previously (excepted for patients already under tucatinib who continue without interruption).

  2. Patients who are pre-treated with tucatinib and who received a decreased dose of tucatinib (\<300mg twice daily) are not eligible in the safety run-in phase.
  3. Have used a strong or CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment (see Appendix 4 and 5)
  4. Patients unable for any reason to undergo MRI of the brain.
  5. or requiring immediate symptomatic treatment or a high dose of therapy (≥2mg/day dexamethasone or equivalent).
  6. Have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases notwithstanding CNS-directed therapy
  7. Any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1 at time of treatment start, with the following exceptions:

    1. Alopecia and neuropathy (must have resolved to ≤ Grade 2)
    2. Congestive Heart Failure (must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely)
    3. Anemia (must have resolved to ≤ Grade 2)
  8. Patients who have had a last dose of IV chemotherapy within 21 days, last dose of oral cytotoxic chemotherapy, radiotherapy, biological therapy, or investigational therapy within 14 days prior to treatment start. This does not apply to patients already under tucatinib who continue without interruption.
  9. Patients who have had any major surgery within 28 days prior to inclusion.
  10. Have evidence within 2 years of the start of study treatment of another that required systemic treatment. This does not apply to patients already under tucatinib who continue without interruption.
  11. Concomitant use of other agents for the treatment of cancer or any investigational agent(s).
  12. Women who are either pregnant, lactating, planning to get pregnant
  13. Have a serious concomitant systemic disorder (eg, active infection or a gastrointestinal disorder causing symptoms such as nausea, vomiting, diarrhea, or profound immune suppression) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol, including but not limited to the following:

    1. Have known (HIV) infection.
    2. Active or C virus infection (screening required) or have other known chronic liver disease
    3. Severe renal impairment, interstitial lung disease (ILD), severe dyspnea at rest or requiring oxygen therapy, liver disease diagnosed with A or higher cirrhosis or history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in clinically significant diarrhea.
  14. Have clinically significant cardiopulmonary disease such as:

    • ventricular arrhythmia requiring therapy,
    • uncontrolled hypertension (defined as persistent systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medications), or
    • any history of symptomatic CHF
    • severe dyspnea at rest ( Grade 3 or above) due to complications of advanced malignancy
    • hypoxia requiring supplementary oxygen therapy except when oxygen therapy is needed only for obstructive sleep apnea
    • presence of ≥ Grade 2 prolongation on screening
    • conditions potentially resulting in drug-induced prolongation of the QT interval or torsade de pointes:
  1. Congenital or acquired long QT syndrome 2. Family history of sudden death 3. History of previous drug induced QT prolongation 4. Current use of medications with known and accepted associated risk of QT prolongation (see row "Accepted Association" in Appendix 8 15. Have known myocardial infarction or unstable angina within 6 months prior to first dose of study treatment 16. Require therapy with warfarin or other coumarin derivatives (non-coumarin anticoagulants are allowed) 17. Have inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medication 18. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient .
  1. Person deprived of liberty or placed under a legal protection regime with representation of the person.
  1. Inability to comply with medical monitoring of the trial for geographic, social or psychological reasons.

-

Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Combination of tucatinib-Oral VP16-trastuzumab

    The safety run in part will be a safety evaluation including 6 patients at dose D of Oral VP16 per day, trastuzumab 600mg SC flat dose or 6mg/kg IV every 3 weeks and tucatinib 300mg PO BID. The evaluable population for DLT in this Part 1 is defined as patients who have completed the first 2 cycles of treatment (i.e.6 weeks) and received 100% of the planned dose of tucatinib-Oral VP16-trastuzumab.Patients treated at Dose Recommended during the safety run-in part will be considered as evaluable for the part II.

    Drug: Tucatinib in Combination of Oral VP16 and trastuzumab

Interventions

  • DrugTucatinib in Combination of Oral VP16 and trastuzumab

    Combination of tucatinib-Oral VP16-trastuzumab

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TucatinibStudies of TucatinibTucatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR

    The objective response rate (ORR) is defined as the best response defined as complete or partial response occurring within the first 6 months of treatment, assessed by the investigators (according to RECIST v1.1 criteria)

    Time frame: 6 months

Secondary outcomes

  1. Serious adverse events

    Serious adverse events (SAEs)according to NCI CTCAE v5.0, by grade and their relationship to tucatinib-Oral VP16-trastuzumab.

    Time frame: From inclusion until 30 days after the last dose of IMP, up to 24 months

  2. Adverse events

    Adverse events (AEs) according to NCI CTCAE v5.0, by grade and their relationship to tucatinib-Oral VP16-trastuzumab.

    Time frame: From inclusion until 30 days after the last dose of IMP, up to 24 months

  3. Progression free survival

    Progression free survival (PFS) is defined as the time from the date of inclusion until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause. The measure of interest is the median PFS

    Time frame: From inclusion until Progression or Death, up to 24 months

  4. Overall survival

    Overall survival (OS) is defined as the time from inclusion to the date of death due to any cause. The measure of interest is the median OS (if reached).

    Time frame: From inclusion until Progression or Death, up to 24 months

  5. Duration of response

    Duration of response (DoR) as defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause. The measure of interest is the median DoR

    Time frame: From inclusion until Progression or Death, up to 24 months

  6. Time to response

    Time to response (TTR) as defined as the time from the start of treatment to the first ORR observed for patients who achieved a CR or PR. The measure of interest is the median TTR.

    Time frame: 6 months

  7. Clinical benefit rate

    Clinical benefit rate (CBR) is defined as the percentage of patients with CR, PR, or stable disease (SD) according to RECIST 1.1, as assessed by the investigator at the local site. The measure of interest is CBR at 24 weeks

    Time frame: 6 months

  8. EQ-5D-5L scale

    The measure of interest is the mean difference in the change from baseline in EQ-5D-5L scale. Time to deterioration in pain, physical functioning, role functioning and global health status/QoL. The EQ VAS score is rated on a scale of 0-100 points. 0 points correspond to the worst possible health status

    Time frame: From inclusion until Progression or Death, up to 24 months

07

Study locations

9 of 13 sites recruiting
  • Centre Jean Perrin
    Clermont-Ferrand, Clermont Ferrand 63011, France
    Suspended

    Not enrolling at this site.

  • CHU Amiens Picardie-Site Sud
    Amiens, 80054, France
    Recruiting
    • MOREIRA Aurélie, MD · Contact
    • Aurélie MOREIRA, MD · Principal investigator
  • Institut Sainte Catherine
    Avignon, 84000, France
    Recruiting
    • Julien GRENIER, MD · Contact
    • Julien GRENIER, MD · Principal investigator
  • Centre François Baclesse
    Caen, 14076, France
    Recruiting
    • George EMILE, MD · Contact
    • George EMILE, MD · Principal investigator
  • Centre Georges-François Leclerc
    Dijon, 21079, France
    Recruiting
    • Isabelle DESMOULIN, MD · Contact
    • Isabelle DESMOULIN, MD · Principal investigator
  • Centre Oscar Lambret
    Lille, 59020, France
    Recruiting
    • Stéphanie BECOURT, MD · Contact
    • Stéphanie BECOURT, MD · Principal investigator
  • Institut Du Cancer Montpellier
    Montpellier, 34298, France
    Suspended

    Not enrolling at this site.

  • Hôpital Privé du Confluent
    Nantes, 44277, France
    Recruiting
    • Cyriac BLONZ, MD · Contact
    • Cyriac BLONZ, MD · Principal investigator
  • Institut Curie
    Paris, 75005, France
    Recruiting
    • Delphine LOIRAT, MD · Contact
    • Delphine LOIRAT, MD · Principal investigator
  • Hopital Saint-Louis Ap-Hp Senopole
    Paris, 75010, France
    Not yet recruiting
    • Delphine COCHEREAU, MD · Contact
    • Delphine COCHEREAU, MD · Principal investigator
  • Centre CARIO-Hôpital Privé des Côtes d'Armor (HPCA)
    Plerin, 22190, France
    Recruiting
    • Jérôme MARTIN-BABAU, MD · Contact
    • Jérôme MARTIN-BABAU, MD · Principal investigator
  • Institut Curie
    Saint Cloud, 92210, France
    Recruiting
    • Florence LEREBOURS, MD · Contact
    • Florence LEREBOURS, MD · Principal investigator
  • Oncopole Claudius Regaud
    Toulouse, 31059, France
    Suspended

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific reserach, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 48 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2023
First posted
Jul 21, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Dec 19, 2027
CompletionEst.
Dec 19, 2028
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05955170
Lead sponsor
Institut Curie
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Dec 19, 2023
Primary completion
Dec 19, 2027 (estimated)
Completion
Dec 19, 2028 (estimated)
Last update
Mar 27, 2025

Study contacts

Fouzia Azzouz
Contact
drci.promotion@curie.fr
0147112366
Sandra Nespoulous
Contact
drci.promotion@curie.fr
0147111654
François-Clément Bidard
principal investigator · Institut Curie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Tucatinib

Start the discussion